Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
36.4M
-
Number of holders
-
35
-
Total 13F shares, excl. options
-
25.6M
-
Shares change
-
+25.6M
-
Total reported value, excl. options
-
$593M
-
Value change
-
+$593M
-
Number of buys
-
35
-
Price
-
$23.26
Significant Holders of Rapport Therapeutics, Inc. - Common Stock, $0.001 par value (RAPP) as of Q2 2024
35 filings reported holding RAPP - Rapport Therapeutics, Inc. - Common Stock, $0.001 par value as of Q2 2024.
Rapport Therapeutics, Inc. - Common Stock, $0.001 par value (RAPP) has 35 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25.6M shares
of 36.4M outstanding shares and own 70.18% of the company stock.
Largest 10 shareholders include FMR LLC (4.98M shares), ARCH Venture Management, LLC (3.73M shares), Cormorant Asset Management, LP (2.94M shares), Capital International Investors (2.6M shares), JOHNSON & JOHNSON (2.5M shares), Sofinnova Investments, Inc. (1.95M shares), T. Rowe Price Investment Management, Inc. (1.54M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.36M shares), ALLIANCEBERNSTEIN L.P. (1.09M shares), and PERCEPTIVE ADVISORS LLC (748K shares).
This table shows the top 35 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.